This information is intended for HCP only. This is a prescription based drug. Please consult your doctor if you need more information.
Gazyva is an engineered monoclonal antibody designed to attach to CD20, a protein expressed on certain B cells, but not on stem cells or plasma cells. Gazyva is designed to attack and destroy targeted B-cells both directly and together with the body's immune system. It is currently approved:
In combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia.
In combination with bendamustine followed by Gazyva monotherapy, for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab-containing regimen.
In combination with chemotherapy followed by Gazyva monotherapy in patients achieving at least a partial remission, for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma.
In case of any adverse events or safety queries, please contact:
If you have a scientific query related to one of Roche's products, please contact:
M-PK-00001707
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country.Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.
Please be aware that you are leaving this website.